VALN Valneva SE
QT41| Index | — | P/E | — | EPS (ttm) | -2.12 | Insider Own | — | Shs Outstand | 94.65M | Perf Week | 3.61% |
| Market Cap | 515.84M | Forward P/E | 8.54 | EPS next Y | 0.64 | Insider Trans | — | Shs Float | 85.68M | Perf Month | -7.63% |
| Enterprise Value | 616.84M | PEG | — | EPS next Q | -0.29 | Short Float | 0.22% | Perf Quarter | 7.50% | ||
| Income | -185.00M | P/S | 3.09 | EPS this Y | — | Short Ratio | 2.53 | Perf Half Y | 1.87% | ||
| Sales | 167.00M | P/B | 5.55 | EPS next Y | — | ROA | -40.60% | Short Interest | 191.92K | Perf YTD | -38.21% |
| Book/sh | 0.98 | P/C | 3.71 | EPS next 5Y | — | ROE | -152.15% | 52W High | 12.18 -55.25% | Perf Year | -40.24% |
| Cash/sh | 1.47 | P/FCF | — | EPS past 3/5Y | — | ROIC | -40.48% | 52W Low | 4.75 14.74% | Perf 3Y | -53.02% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -19.67% 9.35% | Gross Margin | 16.40% | Volatility | 3.11% 3.27% | Perf 5Y | -87.89% |
| Dividend TTM | — | EV/Sales | 3.69 | EPS Y/Y TTM | — | Oper. Margin | -86.68% | ATR (14) | 0.23 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.69 | Sales Y/Y TTM | -21.60% | Profit Margin | -110.29% | RSI (14) | 42.12 | Recom | 2.67 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.16 | EPS Q/Q | -156.43% | SMA20 | -3.50% | Beta | 1.37 | Target Price | 14.00 |
| Payout | 0.00% | Debt/Eq | 2.58 | Sales Q/Q | -25.45% | SMA50 | -11.88% | Rel Volume | 0.10 | Prev Close | 5.71 |
| Employees | 674 | LT Debt/Eq | 2.32 | Earnings | Nov 19 | SMA200 | -20.10% | Avg Volume | 78.08K | Price | 5.45 |
| IPO Date | May 05, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -121.64% -17.75% | Net Debt/EBITDA | — | Volume | 7,929 | Change | -4.55% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-22-26 | Downgrade | Goldman Sachs | Neutral → Sell | |
| Apr-16-26 | Reiterated | Guggenheim | Buy | $13 → $11 |
| Aug-25-25 | Reiterated | Jefferies | $18 → $14 | |
| Mar-24-25 | Reiterated | Guggenheim | Buy | $15 |
| Jun-28-24 | Reiterated | HC Wainwright & Co. | Buy |
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 167 | 197 | 183 | 166 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 140 | 121 | 107 | 109 | — | — | — | — | — | |
| Gross Profit | 28 | 76 | 77 | 57 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 75 | 84 | 103 | 104 | — | — | — | — | — | |
| Research and Development | 98 | 96 | 80 | 65 | — | — | — | — | — | |
| Other Operating Expense | -10 | -12 | -121 | -23 | — | — | — | — | — | |
| Operating Income | -135 | -92 | 14 | -89 | — | — | — | — | — | |
| Interest Expense | 48 | 47 | 26 | 25 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | 11 | -1 | 7 | — | — | — | — | — | |
| Net Income Before Taxes | -185 | -129 | -12 | -107 | — | — | — | — | — | |
| Income Taxes | 0 | 1 | 1 | 3 | — | — | — | — | — | |
| Consolidated Net Income | -185 | -130 | -13 | -110 | — | — | — | — | — | |
| Net Income From Continuing Operations | -185 | -130 | -13 | -110 | — | — | — | — | — | |
| Net Income | -185 | -130 | -13 | -110 | — | — | — | — | — | |
| EPS (Recurring) | -2.12 | -1.49 | -0.18 | -1.58 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.12 | -1.49 | -0.18 | -1.58 | — | — | — | — | — | |
| EPS (Diluted) | -2.12 | -1.49 | -0.18 | -1.58 | — | — | — | — | — | |
| EBITDA | -109 | -57 | 35 | -62 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.10 | 3.76 | 1.67 | 4.31 | — | — | — | — | — | |
| Gross Margin | 16.77 | 38.58 | 42.08 | 34.34 | — | — | — | — | — | |
| Operating Margin | -80.84 | -46.70 | 7.65 | -53.61 | — | — | — | — | — | |
| Net Margin | -110.78 | -65.99 | -7.10 | -66.27 | — | — | — | — | — | |
| Shares Outstanding | 95 | 84 | 70 | 69 | — | — | — | — | — | |
| Market Capitalization | 518 | 741 | 306 | 716 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |